LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

Search

Crinetics Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

34.07 0.44

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

33.25

Максимум

34.71

Ключови измерители

By Trading Economics

Приходи

-19M

-116M

Продажби

670K

1M

Марж на печалбата

-11,216.004

Служители

437

EBITDA

-19M

-129M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+109.09% upside

Дивиденти

By Dow Jones

Следващи печалби

11.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

666M

3.3B

Предишно отваряне

33.63

Предишно затваряне

34.07

Настроения в новините

By Acuity

15%

85%

20 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.09.2025 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15.09.2025 г., 16:43 ч. UTC

Значими двигатели на пазара

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15.09.2025 г., 16:42 ч. UTC

Значими двигатели на пазара

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15.09.2025 г., 16:35 ч. UTC

Значими двигатели на пазара

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15.09.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.09.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15.09.2025 г., 23:34 ч. UTC

Пазарно говорене

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15.09.2025 г., 22:48 ч. UTC

Пазарно говорене

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15.09.2025 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

CSL Expects Commercial Launch in 2029

15.09.2025 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15.09.2025 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15.09.2025 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

CSL to Have Right to Exercise Option Based on Phase 3 Data

15.09.2025 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15.09.2025 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15.09.2025 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15.09.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15.09.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.09.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15.09.2025 г., 19:14 ч. UTC

Пазарно говорене

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15.09.2025 г., 18:16 ч. UTC

Пазарно говорене

Gold Powers to New High -- Market Talk

15.09.2025 г., 18:05 ч. UTC

Пазарно говорене

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15.09.2025 г., 17:50 ч. UTC

Придобивния, сливания и поглъщания

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15.09.2025 г., 17:10 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.09.2025 г., 17:10 ч. UTC

Пазарно говорене

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15.09.2025 г., 16:52 ч. UTC

Пазарно говорене

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.09.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Crinetics Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

109.09% нагоре

12-месечна прогноза

Среден 71.09 USD  109.09%

Висок 97 USD

Нисък 36 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Crinetics Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

11

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

30.39 / 33.46Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

20 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat